Professional Documents
Culture Documents
Mitrev 2016
Mitrev 2016
www.elsevier.com/locate/buildenv
PII: S1053-0770(16)30184-7
DOI: http://dx.doi.org/10.1053/j.jvca.2016.06.012
Reference: YJCAN3725
To appear in: Journal of Cardiothoracic and Vascular Anesthesia
Received date: 23 September 2015
Cite this article as: Ludmil Mitrev, Natalie Trautman, Ratna Vadlamudi, Nayan
Desai and Sajjad A. Sabir, Anesthesia and TEE for WATCHMAN TM Device
Implantation, Journal of Cardiothoracic and Vascular Anesthesia,
http://dx.doi.org/10.1053/j.jvca.2016.06.012
This is a PDF file of an unedited manuscript that has been accepted for
publication. As a service to our customers we are providing this early version of
the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting galley proof before it is published in its final citable form.
Please note that during the production process errors may be discovered which
could affect the content, and all legal disclaimers that apply to the journal pertain.
Anesthesia and TEE for WATCHMANTM Device Implantation
Authors: 1
Ludmil Mitrev, M.D. , e-mail: Mitrev-Ludmil@cooperhealth.edu
1
Natalie Trautman, M.D. , e-mail: Trautman-Natalie@CooperHealth.edu
2
Ratna Vadlamudi, M.D. , e-mail: RVADLAM@emory.edu
3
Nayan Desai, M.D. , e-mail: Desai-Nayan@CooperHealth.edu
3
Sajjad A Sabir, M.D. , e-mail: sabir-sajjad@CooperHealth.edu
1
Department of Anesthesiology and Division of Cardiothoracic Anesthesiology, Cooper University
(856) 968-7334
Acknowledgements
The authors wish to thank Kelly Speich, MS for his assistance with gross anatomy images.
Keywords
Watchman device; left atrial appendage closure device; atrial fibrillation; ischemic stroke.
1
Anesthesia and TEE for WATCHMANTM Device Implantation
Abstract
Only 30% to 50% of patients with non-valvular atrial fibrillation are treated with
adherence and the side effect profile of such therapy.1 Several left atrial
Introduction
A 2015 annual report from the American Heart Association estimated the annual
which 77% were new events, and the remainder – recurrent strokes. Eighty-
seven percent of all strokes are ischemic. The age-adjusted death rate per
100,000 population in 2009-2011 was 38.9, accounting for some 128,932 stroke-
diseases, stroke ranked 4th among all causes of death in the United States,
behind diseases of the heart, cancer, and chronic lower respiratory diseases 2.
The global prevalence of stroke was 33 million cases in 20103, and stroke was
2
second only to ischemic heart disease in terms of mortality on a global basis,
Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk
5-fold in all age groups. The attributable risk of stroke related to AF increases
with age, and may be substantially underestimated, due to the fact that AF can
contribute to greater than 20% of strokes, and many efforts are directed towards
anticoagulation and has been effective in reducing the risk of stroke by ~60%. 5
and edoxaban have shown comparable efficacy to warfarin with potentially better
patients are treated with it, due to various barriers and contraindications. Chief
among those barriers is the elevated risk of bleeding associated with warfarin or
vicinity of 1.4% to > 3% per year.10 The incidence of major hemorrhage with
devices have been developed. Those devices are inserted into the LAA through
3
catheter-based delivery systems, via transseptal puncture from the right to left
device (Boston Scientific Corp., Marlborough, MA), the Amplatzer™ Cardiac Plug
(ACP) and Amplatzer™ Amulet™ devices (St. Jude Medical, St. Paul, MN), and
the Coherex WaveCrest® device (Coherex Medical Inc., Salt Lake City, UT).11 A
review of the FDA device approval web pages on August 30th, 2015, revealed
that only the Watchman device had FDA approval in the United States. All of the
European Union.
The Lariat® suture delivery device (SentreHeart Inc., Redwood City, CA) deploys
a different strategy for ligation of the LAA that combines a transseptal and an
surface of the LAA ostium requires subxiphoid pericardial access. This may not
and is not suitable for all LAA anatomies. The Lariat device has received 510(k)
clearance by the FDA for facilitation of suture placement and knot tying in
surgical applications where soft tissues are being approximated, but essentially
all of its use has been as an LAA exclusion device.12, 13 Although case series do
exist describing results with the device both in Europe12 and the United States14,
is electromechanical isolation of the left atrial myocardium from the LAA, the
4
latter in itself being a known trigger for AF15, 16. A future randomized controlled
trial (AMAZE Trial) will evaluate the use of the Lariat device for the ligation of the
Several methods for the ligation of the LAA during concomitant cardiac surgery
exist as well. Postoperative TEE data suggests that up to 60% of these closures
may be unsuccessful, as judged by the presence of LAA remnants > 1cm, flow in
the LAA remnant, or thrombi in the LAA remnant.17 Despite the uncertainty about
the efficacy of varying surgical approaches to LAA ligation and its effects on the
guideline for the management of patients with AF from the American College of
surgery (level of evidence C).18 In the same guideline, the percutaneous devices
such as the Watchman device were briefly described, but the authors did not find
use at the time. Since the publication of that guideline, FDA has approved the
Cardiology guidelines for the management of atrial fibrillation gave class IIb (LOE
B) recommendation for use of Watchman device for patients at high risk for
5
In the remainder of this article, we focus on the Watchman device and the
The left atrial appendage is a remnant of the primary atrium, which forms during
the third week of embryonic development. It is distinct from the main left atrial
level, contains a high concentration of atrial natriuretic factor. The left atrium
proper forms from the outgrowth of the pulmonary veins after the 4th week of
both in non-valvular AF, as well as in patients with mitral valve disease who are
either in AF or sinus rhythm. The LAA is the site of thrombus formation in more
than 90% of patients with non-valvular AF, and in 60% of patients with rheumatic
The shape of the LAA is highly variable. Several predominant morphologies have
recently been described that have gained attention due to their association with
such as the Watchman. Di Biase et al.22 examined 932 patients who were
6
scheduled to undergo AF ablation, with either cardiac CT or MRI, and
subclassified the LAA morphology into 4 types, which they termed “cactus”
(30%), “chicken wing” (48%), “windsock” (19%), and “cauliflower” (3%). The
secondary lobes extending from it in both superior and inferior directions. The
middle part of the dominant lobe, or a folding back of the LAA on itself at some
distance from the perceived LAA ostium. The authors stated that this type of LAA
by a single, elongated lobe of the LAA as the primary structure, although it, too,
can have secondary or tertiary lobes. Lastly, the cauliflower variety presented as
a LAA with limited overall length, and a variable number of lobes. The feature
distinguishing it from the cactus variety is the absence of a dominant lobe. This
subtype could also have a complex internal structure, and irregular or ovoid
shape of the LAA orifice. Some authors have referred to this anatomical variant
as a broccoli subtype.1
Using two separate multivariate logistic regression models and controlling for
CHADS2 score, gender, and AF types, Di Biase et al. demonstrated that patients
with the chicken wing LAA morphology were significantly less likely to have had a
history of stroke or TIA than those with the remaining subtypes. Although the
overall size of the LAA has been reported in autopsy studies to correlate with the
risk of stroke or TIA, this association was not corroborated in the Di Biase study.
7
Figures 2-5 demonstrate the TEE imaging equivalents of the four LAA
because the size and depth of the main lobe of the LAA relative to the LAA
ostium will determine the size of the device to be used, and the relative ease of
successful occlusion. It is worth noting that ideal images that conform to one of
the aforementioned shapes can be difficult to obtain via TEE, and may challenge
anchors, along with a fabric cap, or skirt (Figure 6).1 The cap is crafted from
micron filter designed to block emboli from exiting the LAA. It is available in 21,
24, 27, 30 and 33 mm sizes (device diameter). The approved indication is for
LAA occlusion in patients who are at an increased risk for stroke and systemic
for anticoagulation with warfarin, but have an appropriate rationale to seek a non-
comorbidities, age, and in the latter case also gender.18, 23-25 Intracardiac
8
thrombus, presence of ASD or PFO occlusion device, or inability to tolerate
device Directions For Use document does not distinguish between absolute and
treated as absolute.
The patient is typically maintained on aspirin and warfarin for 45 days post
warfarin was discontinued after 45 days in 92% of patients, and in > 99% after 12
cardiologist.
The safety and long-term efficacy of the Watchman device has been evaluated in
PROTECT AF trial in the United States and Europe compared LAA occlusion
with the Watchman device versus warfarin anticoagulation. Patients with non-
valvular atrial fibrillation and at least one of the following were included: previous
9
stroke or TIA, congestive heart failure, diabetes, hypertension, or age greater
than 75. The primary efficacy endpoint in this study was occurrence of ischemic
within up to 3 years. The trial showed that at 3.8 years of follow-up, there was a
primary event rate of 2.3 events per 100 patient-years for the device group,
compared to a primary event rate of 3.8 events per 100 patient-years for the
warfarin group, thus meeting the criteria for both non-inferiority and superiority. In
the device group, there were lower rates of both cardiovascular mortality and all-
cause mortality.28 The PREVAIL trial showed that use of the Watchman device
was not inferior to warfarin therapy for ischemic stroke prevention, with a
significantly lower early safety events rate than the PROTECT AF trial (2.2%).
aids the anesthesiologist in providing the best care to the patient, and in
procedure. TEE is essential for identifying the morphology, size and depth of the
LAA, number and location of lobes relative to LAA ostium, and for proper
sufficient, particularly in cases where the LAA anatomy is complex and involves
10
device, aneurysmal interatrial septum, PFO, ASD and significant mitral
regurgitation, is essential. TEE also allows for rapid recognition of any procedural
services in this type of procedure, similar to the TEE services provided during
and the LAA ostium size and usable length are measured in 4 dimensions: a) 0 –
the ME aortic valve view; c) 90° in the ME two-chamber view; and d) 120 – 135°
in the aortic valve long-axis view.1, 29 One can also utilize X-plane at 0° to obtain
a simultaneous 90° orthogonal imaging plane and an X-plane from 45° will yield a
135° view. The 0° and 135° views often show the largest ostial diameter. When
using 2D multiplane TEE, the ostium diameter should be obtained from the level
of the circumflex artery or the superior edge of the mitral valve annulus to a point
2cm from the limbus of the left upper pulmonary vein. Three-dimensional TEE
can also be used to assess the size of the LAA ostium (Fig. 7).30-32 The 10 active
fixation anchors on the LAA side of the device engage the tissue to offer device
stability, but the Watchman device is kept in place largely by radial forces
generated from compression of the device. The goal, therefore, is for a 12-20%
11
accordingly, is selected to be some 12-20% wider than the widest measurement
of the LAA orifice. For example, for a LAA orifice of 19mm, a 21mm device will
typically be selected. The maximum LAA ostium and the LAA depth
measurements are used as a basis for selecting the device size. The length of
the Watchman device is the same as the device size. Therefore, the dominant
lobe of the LAA should ideally be at least as deep as the device size selected in
order to accommodate the device. This ‘usable depth’ of the LAA is measured
from the ostium line to the apex of the LAA or the deepest portion of its dominant
lobe (Fig. 2, 3 and 4). The maximum LAA ostium size should be between 17 to
consider during the baseline TEE exam include the pulmonary veins and flow,
atheromatous disease.
The absence of clot in the atrium or LAA must be verified. The morphology of the
LAA should also be assessed. The windsock type of LAA is easiest to occlude as
it consists of one long tube-like space. The cauliflower type LAA may be short
relative to the size of its orifice, making it hard to occlude with a Watchman
device. Likewise, the chicken wing type may have a short proximal portion, which
successful even if the protrusion of the shoulder is 40-50% of the device depth.33
12
As the Watchman device skirt covers 50% of the device surface, this protruding
Next, the echocardiographer should guide the position of the transseptal sheath
inferoposterior part of the septum.1 The catheters are more difficult to manipulate
and position if the transseptal puncture is too close to the plane of the mitral
valve orifice. In bicaval view the transseptal sheath and catheter are slowly pulled
inferiorly from SVC towards the mid portion of the septum. A leftward tenting of
the interatrial septum can be seen when the transseptal needle comes into
contact with the septum (Figure 8). Next, a modified short axis view at the aortic
valve level in the mid esophagus is used to position the transseptal access
sheath posteriorly (away from aortic valve) with a clockwise rotation. Another
useful ME TEE view for transseptal puncture guidance is the bicaval view with an
X-plane through the tented site demonstrating modified short axis view at the
aortic valve level at the same time. Live 3D or 3D zoom can also be used to
confirm the proper transseptal puncture site, although use of 3D images for this
estimation of the LAA ostial size from hypovolemia (since the patients are NPO
13
After the needle and sheath are advanced into the left atrium, the sheath is
further advanced into the left upper pulmonary vein (LUPV). After administration
of 100 IU/kg heparin, the WATCHMAN access sheath is passed over a guidewire
into the LUPV. Activated clotting time is maintained at 200-300 seconds and is
WATCHMAN access sheath. With the help of TEE, it is then pulled back from the
LUPV and inserted into the distal portion of the LAA. The appropriate position is
advanced in the correct position in the LAA over the pigtail catheter, the pigtail
catheter is removed, and, after rechecking the access sheath positioning, the
Watchman delivery system is introduced. The delivery catheter tip position in the
retracting the access sheath and delivery catheter assembly. At this point, the
A set of device release criteria should then be confirmed using fluoroscopy and
TEE. The release criteria are Position, Anchor, Size and Seal (PASS). Position is
just distal to the ostium, and that it spans the entire LAA ostium. Too distal
residual flow in the LAA. Too shallow a placement may lead to low compression
14
or unstable device. In addition, the device may protrude too far into the LA.
Three-dimensional TEE can add useful information about the fit and position of
the device.29 The invasive cardiologist or surgeon verifies the device anchoring
by using a “tug test” that involves retracting and releasing the deployment knob.
An anchored device should gently tug on the LAA. Size is verified by measuring
the maximum diameter of the Watchman device in the same 4 dimensions used
to measure the ostium size on TEE. The “threaded insert” (Fig. 9) must be visible
when measuring on echo to ensure the device was measured at its widest cross-
section in all angles. The size of the device, once deployed, should be 8 to 20%
smaller than its original dimension as this degree of compression yields adequate
radial pressure that helps keep the device in place. Finally, seal is verified using
color flow Doppler and angiography. All of the lobes of the LAA should be sealed.
Small peri-device leaks are permissible (<5mm) and may not require
repositioning of the device1. However, if gaps or leaks greater than 5mm exist,
The procedure ends when the delivery system is removed and local hemostasis
15
Throughout deployment and before case completion, the echocardiographer
interference with the function of the mitral valve or pulmonary vein flow, or
thrombus formation. Typically at the end of the procedure, a small ASD can be
seen at the site of transseptal puncture, normally with left to right shunt which
Data from the PROTECT AF trial showed that the most common peri-procedural
complications were pericardial effusions and air embolism causing stroke.1 The
sheath within the LAA, the transseptal puncture, or the tug test. The air embolism
could have arisen from the large 12F transseptal access sheath. Low LAA
anesthesia. Standard ASA monitors with arterial blood pressure recording are
utilized. We suggest techniques that will ensure rapid emergence and extubation
at the end of the procedure. Blood gas analysis and activated clotting time
16
After device deployment, the ACT is allowed to drift back to the patient’s
baseline, and the patient is extubated. The patient will recover in the post-
anesthesia care unit and is then transferred to a cardiology floor bed until he or
she is ready for discharge. Select patients are transferred to the cardiology care
as the type of anesthesia for this procedure, emergency airway devices should
be readily available.1
Conclusions
of thromboembolic strokes are the result of thrombi arising in the LAA in patients
therapy for those patients, but is not suitable for all due to the risk of hemorrhagic
17
complications. The WATCHMANTM Left Atrial Appendage Closure Device
CHA2DS2-VASc scores.
Both general anesthesia and monitored anesthesia care have been used
the device, together with angiography. The ability to develop multiplanar images
Experience with the Watchman device and the availability of future device
alternatives will likely make percutaneous LAA occlusion more common. Use of
alternatives to TEE such as intracardiac echo to image the LAA have been
and universal reliability as a peri-procedural guidance tool, TEE will likely remain
18
Figure Legends
Figure 7. 3D TEE full volume multiplane reconstruction of the LAA, with diameter
19
References
atrial appendage closure device for atrial fibrillation. J Vis Exp. 2012.
18:185-189, 2009.
8. Granger CB, Alexander JH, McMurray JJ, et al.: Apixaban versus warfarin
20
9. Patel MR, Mahaffey KW, Garg J, et al.: Rivaroxaban versus warfarin in
11. Lanigan MJ, Chaney MA, Nathan S, et al.: Case 4-2015: use of the lariat
12. Bartus K, Han FT, Bednarek J, et al.: Percutaneous left atrial appendage
suture ligation using the LARIAT device in patients with atrial fibrillation:
the differences in the location and type of leaks and their clinical
14. Massumi A, Chelu MG, Nazeri A, et al.: Initial experience with a novel
2010.
21
16. Han FT, Bartus K, Lakkireddy D, et al.: The effects of LAA ligation on LAA
17. Kanderian AS, Gillinov AM, Pettersson GB, et al.: Success of surgical left
18. January CT, Wann LS, Alpert JS, et al.: 2014 AHA/ACC/HRS guideline for
2014.
19. Camm AJ, Lip GY, De Caterina R, et al.: 2012 focused update of the ESC
20. Al-Saady NM, Obel OA, Camm AJ: Left atrial appendage: structure,
722, 2013.
22
atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol.
60:531-538, 2012.
24. Lane DA, Lip GY: Use of the CHA(2)DS(2)-VASc and HAS-BLED scores
25. Lip GY, Tse HF, Lane DA: Atrial fibrillation. Lancet. 379:648-661, 2012.
26. Holmes DR, Jr., Kar S, Price MJ, et al.: Prospective randomized
28. Holmes DR, Reddy VY, Turi ZG, et al.: Percutaneous closure of the left
374:534-542, 2009.
10, 2011.
23
30. Shah SJ, Bardo DM, Sugeng L, et al.: Real-time three-dimensional
2008.
32. Nakajima H, Seo Y, Ishizu T, et al.: Analysis of the left atrial appendage by
106:885-892, 2010.
1220, 2014.
34. Chan NY, Lau CL, Tsui PT, et al.: Experience of left atrial appendage
off piste? Closure of the left atrial appendage using ICE and local
24
Table 1. CHADS2 and CHA2DS2-VASc scoring systems
25
Table 2. Contraindications to Watchman device implantation
®
Based on WATCHMAN Directions For Use,
https://www.bostonscientific.com/content/dam/Manuals/us/current-rev-en/90746221-
01C_Watchman%20Device_DFU_en-US_s.pdf
th
Last accessed November 28 , 2015.
26
27
28
29
30
31
32
33
34